The study met its primary endpoint of radiographic progression free survival, which was significantly prolonged with the ...

The 2026 PSMA & Beyond conference featured a developing novel radioligands session and presentation by Dr. Philipp Backhaus discussing the initial experience with APC3. The history of ACP3 goes back ...

PSMA radioligand therapy is associated with significant reductions in PSA levels among select patients with metastatic prostate cancer, suggesting tumor responses. Prostate-specific membrane antigen ...

In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen deprivation therapy (ADT) and chemotherapy more than doubled biochemical ...

Prostate cancer liver metastases: Genomic profiling and clinical outcomes. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not include a full ...

Concomitant G-CSF use in maintaining an efficacious dose and safe delivery of docetaxel in combination with darolutamide in patients with metastatic hormone sensitive prostate cancer (mHSPC): ARASENS, ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

A renewed interest in radiopharmaceuticals has led to ground-breaking research and improved outcomes in patients with prostate cancer, according to experts. Radiopharmaceuticals have been used to ...

The Prostate Cancer Foundation (PCF) today announced a $10 million unrestricted gift from an anonymous donor to launch a TACTICAL (Therapy ACceleration To Intercept CAncer Lethality) Award, which will ...

Prostate-specific membrane antigen (PSMA)-PET appeared to cut the risk for treatment failure by half in patients receiving salvage radiotherapy (RT) after radical prostatectomy, without increasing ...

Reston, VA (October 13, 2025)--A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently and reliably assess prostate cancer progression or regression during ...